O96013 (PAK4_HUMAN) Homo sapiens (Human)
Serine/threonine-protein kinase PAK 4 UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
47 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| CDC42 binds PAK4 via an extended GTPase-effector interface - 3 peptide: PAK4cat, PAK4-N45, CDC42 |
Heteromer P60953; | 1×ANP; 1×GNP; 1×MG; | ||||
| Assess | ||||||
| Catalytic domain of human PAK4 with RPKPLVDP peptide |
Heteromer | |||||
| Assess | ||||||
| Catalytic domain of human PAK4 with RPKPLVDP peptide |
Heteromer | 1×ANP; | ||||
| Assess | ||||||
| In vitro Crystal Structure of PAK4 in complex with Inka peptide |
Heteromer Q96EL1; | |||||
| Assess | ||||||
| PAK4 kinase domain in complex with LIMK1 Thr508 substrate peptide |
Heteromer P53667; | |||||
| Assess | ||||||
| PAK4 kinase domain in complex with beta-catenin Ser675 substrate peptide |
Heteromer P35222; | |||||
| Assess | ||||||
| CDC42 binds PAK4 via an extended GTPase-effector inteface - 2 peptide: PAK4FL, CDC42 - UNREFINED |
Heteromer P60953; | |||||
| Assess | ||||||
| PAK4cat in complex with Integrin beta5 760-770 peptide |
Heteromer P18084; | |||||
| Assess | ||||||
| Integrin beta5(743-774)-linker-PAK4cat(D440N/S474E) |
Heteromer P18084; | 1×ANP; | ||||
| Assess | ||||||
| PAK4cat (D440N/S474E) in complex with Integrin beta5 760-770 peptide |
Heteromer P18084; | 1×ANP; | ||||
| Assess | ||||||
| The crystal structure of the human RAC3 in complex with the CRIB domain of human p21-activated kina… |
Heteromer P60763; | 1×MG; 2×CL; 1×GCP; | ||||
| Assess | ||||||
| Full-length human PAK4 | monomer | 1×ANP; | ||||
| Assess | ||||||
| In cellulo Crystal Structure of PAK4 in complex with Inka | monomer | 1×ATP; 2×MG; | ||||
| Assess | ||||||
| Structure of human p21 activating kinase 4 (PAK4) in complex with a consensus peptide | monomer | 1×SO4; 8×EDO; | ||||
| Assess | ||||||
| The Crystal Structure of P21-Activated Kinases Pak4 from Biortus | monomer | 1×PGE; | ||||
| Assess | ||||||
| Catalytic domain of human PAK4 | monomer | 1×ANP; 1×MG; | ||||
| Assess | ||||||
| Crystal Structure of PAK4 in complex with inhibitor CZg353 | monomer | 1×9EO; 8×EDO; 1×TRS; 1×BCT; | ||||
| Assess | ||||||
| Crystal Structure of PAK4 in complex with inhibitor CZH216 | monomer | 1×8FU; 4×EOH; | ||||
| Assess | ||||||
| PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery | monomer | 1×M4I; | ||||
| Assess | ||||||
| Catalytic domain of human PAK4 with QKFTGLPRQW peptide | monomer | |||||
| Assess | ||||||
| PAC FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery | monomer | 1×M4X; | ||||
| Assess | ||||||
| Crystal Structure of the Human p21-Activated Kinase 4 in Complex with PF-03758309 | monomer | 2×GOL; 1×7KC; | ||||
| Assess | ||||||
| Crystal Structure of PAK4 in complex with inhibitor CZH226 | monomer | 1×8FX; 5×EOH; 3×EDO; | ||||
| Assess | ||||||
| Crystal Structure of the Human p21-Activated Kinase 4 in Complex with (S)-N-(5-(3-benzyl-1-methylpi… | monomer | 1×N53; 1×GOL; | ||||
| Assess | ||||||
| Catalytic domain of human PAK4 | monomer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A | monomer | 1×23D; 2×SO4; 1×CL; | ||||
| Assess | ||||||
| Crystal Structure of PAK4 in complex with inhibitor 55 | monomer | 1×GCC; | ||||
| Assess | ||||||
| PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery | monomer | 1×M56; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 | monomer | 4×EDO; | ||||
| Assess | ||||||
| PAK4 kinase domain in complex with fasudil | monomer | 1×M77; 1×ACT; | ||||
| Assess | ||||||
| Crystal structure of Serine/threonine-protein kinase PAK 4 in complex with Paktide S peptide substr… | monomer | 1×ANP; 2×MG; | ||||
| Assess | ||||||
| Crystal structure of Serine/threonine-protein kinase PAK 4 in complex with Paktide T peptide substr… | monomer | |||||
| Assess | ||||||
| Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors | monomer | 1×2OO; | ||||
| Assess | ||||||
| Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide T p… | monomer | |||||
| Assess | ||||||
| PAK4 kinase domain in complex with Staurosporine | monomer | 1×STU; | ||||
| Assess | ||||||
| Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide S p… | monomer | |||||
| Assess | ||||||
| Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors | monomer | 1×2OQ; | ||||
| Assess | ||||||
| Structure of p21-activated kinase 4 with a novel inhibitor KY-04031 | monomer | 1×NJD; | ||||
| Assess | ||||||
| PAK4 kinase domain in complex with FRAX486 | monomer | 1×981; | ||||
| Assess | ||||||
| Crystal Structure of PAK4 in complex with inhibitor 41 | monomer | 1×G5X; | ||||
| Assess | ||||||
| Crystal Structure of Catalytic Domain of PAK4 | monomer | |||||
| Assess | ||||||
| Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors | monomer | 1×2OL; | ||||
| Assess | ||||||
| Crystal Structure of PAK4 in complex with inhibitor 47 | monomer | 1×GC6; | ||||
| Assess | ||||||
| Crystal structure of P21-activated kinase 4 in complex with an inhibitor compound 29 | monomer | 1×4T6; | ||||
| Assess | ||||||
| Crystal Structure of PAK4 in complex with inhibitor CZH062 | monomer | 1×8FR; | ||||
| Assess | ||||||
| Structure of PAK4 | monomer | 1×67U; | ||||
| Assess | ||||||
| Crystal structure of the human P21-activated kinase 4 | monomer | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4fie.1.A | monomer | 0.64 | 1×ANP; | 98.58 | ||
| Assess | ||||||
3 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 4fie.1.A | monomer | 0.78 | 1×ANP; | 100.00 | |
| Assess | ||||||
| Isoform 3 | 4fie.1.A | monomer | 0.75 | 1×ANP; | 89.10 | |
| Assess | ||||||
| Isoform 4 | 4fie.1.A | monomer | 0.71 | 1×ANP; | 99.76 | |
| Assess | ||||||